Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
Portfolio Pulse from
Kite, a Gilead Company, announced that its CAR T-cell therapy, Yescarta, showed durable response and long-term survival in patients with relapsed/refractory non-Hodgkin lymphomas after five years, according to a Phase 2 study presented at ASH 2024.
December 09, 2024 | 11:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's subsidiary, Kite, reported positive long-term results for Yescarta in treating relapsed/refractory non-Hodgkin lymphomas, potentially boosting Gilead's stock.
The positive long-term results of Yescarta, a product of Gilead's subsidiary Kite, in treating NHL could enhance investor confidence in Gilead's oncology portfolio, potentially leading to a positive impact on Gilead's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90